https://www.guineabissauhealthbulletin.com/article/908434497-clearmind-medicine-announces-evaluation-of-its-psychedelic-based-treatment-meai-for-potential-fda-breakthrough-therapy-designation Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:41:00+00:00 Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation https://ml.globenewswire.com/media/bd17cbf4-8124-4f86-8a4c-1fafbb6785af/small/logo-jpg.jpg https://www.guineabissauhealthbulletin.com/article/908434367-briacell-announces-six-clinical-data-presentations-at-asco-2026 Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:30:00+00:00 BriaCell Announces Six Clinical Data Presentations at ASCO 2026 https://ml.globenewswire.com/media/88b9408d-31d4-4afd-beff-f855719a15d8/small/briacell-logo-square-a-jpg.jpg https://www.guineabissauhealthbulletin.com/article/908434376-tovecimig-demonstrates-statistically-significant-benefit-in-companion-002-randomized-phase-2-3-study-in-patients-with-biliary-tract-cancer Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:30:00+00:00 Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer https://ml.globenewswire.com/media/b8470129-5d30-4368-8074-d77404b65be8/small/compass-logo-rgb-outlines-png.png https://www.guineabissauhealthbulletin.com/article/908434378-nima-s-next-gen-portable-gluten-sensor-wins-gold-stevie-award-for-achievement-in-product-innovation Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:30:00+00:00 NIMA’s Next-Gen Portable Gluten Sensor Wins Gold Stevie® Award for Achievement in Product Innovation https://ml.globenewswire.com/media/a025c49c-a270-4041-92e3-76d50d9bc27f/medium/nima-is-the-2026-gold-stevie-award-winner.png https://www.guineabissauhealthbulletin.com/article/908434384-medicus-pharma-ceo-meets-with-lawmakers-on-energy-commerce-committee-on-capitol-hill Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:30:00+00:00 Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill https://ml.globenewswire.com/media/0f5af1d1-dfba-4810-baac-d1922c0558c1/small/medicus-logo-rgb-05-aspect-1500px-globe-newswire-2-jpg.jpg https://www.guineabissauhealthbulletin.com/article/908434390-weight-watchers-announces-actions-to-utilize-up-to-40-million-to-pay-down-debt Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:30:00+00:00 Weight Watchers Announces Actions to Utilize Up to $40 million to Pay Down Debt https://ml.globenewswire.com/media/f435b439-7f75-4d2f-a6cc-0e4e2ed811ea/small/weightwatchers-wordmark-boldblue-png.png https://www.guineabissauhealthbulletin.com/article/908434404-hcw-biologics-delivers-a-major-update-for-its-t-cell-engager-program-revealing-mechanism-of-action-and-validating-tissue-factor-as-target-for Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:30:00+00:00 HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors https://ml.globenewswire.com/media/5689edc3-6997-43a0-a20c-b34dc5f99b0f/small/hcw-logo-full-color-600x-jpeg-2-jpg.jpg https://www.guineabissauhealthbulletin.com/article/908434422-nervgen-pharma-strengthens-leadership-team-with-appointment-of-keith-vendola-as-chief-financial-officer Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:30:00+00:00 NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer https://ml.globenewswire.com/media/bb42d0ef-06b6-4b90-8389-ca991092aa37/small/nervgen-logo-updated-globenewswire-png.png https://www.guineabissauhealthbulletin.com/article/908434429-cormedix-therapeutics-announces-positive-topline-results-from-phase-iii-respect-trial-assessing-rezzayo-for-the-prophylaxis-of-invasive-fungal Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:30:00+00:00 CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients https://ml.globenewswire.com/media/a14d732c-3f66-4a3c-96bb-7fc8ba5797bb/small/crmd-logo-jpg.jpg https://www.guineabissauhealthbulletin.com/article/908434491-alterity-therapeutics-receives-positive-fda-feedback-following-second-type-c-meeting-on-ath434-phase-3-program-in-multiple-system-atrophy Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:25:00+00:00 Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy https://ml.globenewswire.com/media/0771a9a2-2ac1-4a63-9767-a2b1df74af27/small/alterity-png.png https://www.guineabissauhealthbulletin.com/article/908430295-suja-life-announces-launch-of-initial-public-offering Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:20:40+00:00 Suja Life Announces Launch of Initial Public Offering https://ml.globenewswire.com/media/9022887d-dd69-416f-9a4b-ce5e546d75e4/small/suja-life-horizontal-black-1-png.png https://www.guineabissauhealthbulletin.com/article/908430292-sagimet-biosciences-announces-pricing-of-175-0-million-underwritten-offering-of-series-a-common-stock Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:15:04+00:00 Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock https://ml.globenewswire.com/media/e944daed-3f71-402b-bb23-82149e5c0d26/small/sagimet-logo-for-light-bg-fin-png.png https://www.guineabissauhealthbulletin.com/article/908429883-fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-for-first-quarter-2026 Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:00:00+00:00 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026 https://ml.globenewswire.com/media/3434fc83-4bcf-4d3c-ae26-23e5b1fd4252/small/fulcrum-logo-primary-full-color-rgb-large-png.png https://www.guineabissauhealthbulletin.com/article/908429920-sionna-therapeutics-completes-enrollment-in-precision-cf-phase-2a-trial-evaluating-nbd1-stabilizer-sion-719-added-to-standard-of-care-in Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:00:00+00:00 Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis https://ml.globenewswire.com/media/0cda8c25-e758-4f0d-86f2-875df8411a9a/small/sionna-png.png https://www.guineabissauhealthbulletin.com/article/908430027-secura-bio-announces-journal-of-clinical-oncology-publication-of-final-results-of-duvelisib-primo-phase-2-trial-in-relapsed-refractory-peripheral Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:00:00+00:00 Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma https://ml.globenewswire.com/media/0c6ab6dc-8076-44dc-acba-60a586a93721/small/securabio-brand-rgb-logo-fullcolor-png.png https://www.guineabissauhealthbulletin.com/article/908430111-oruka-therapeutics-announces-positive-week-16-data-for-orka-001-from-the-ongoing-everlast-a-phase-2a-trial-in-moderate-to-severe-plaque-psoriasis Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:00:00+00:00 Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis https://ml.globenewswire.com/media/3950d2d7-850d-459a-9e42-07c642a841c5/small/oruka-full-color-jpg.jpg https://www.guineabissauhealthbulletin.com/article/908430156-intellia-therapeutics-reports-positive-phase-3-results-in-hereditary-angioedema-marking-a-global-first-for-in-vivo-gene-editing Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:00:00+00:00 Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing https://ml.globenewswire.com/media/9b6b17bb-c8a4-4009-b5f8-8cadb4d2296a/small/intellia-jpg.jpg https://www.guineabissauhealthbulletin.com/article/908430163-intellia-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-lonvoguran-ziclumeran-lonvo-z-as-a-one-time-treatment Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:00:00+00:00 Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema https://ml.globenewswire.com/media/9b6b17bb-c8a4-4009-b5f8-8cadb4d2296a/small/intellia-jpg.jpg https://www.guineabissauhealthbulletin.com/article/908430186-harrow-to-report-first-quarter-2026-financial-results-after-market-close-on-may-11-2026 Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:00:00+00:00 Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026 https://ml.globenewswire.com/media/8e0382bf-e00a-4591-87aa-4e90001aabea/small/bw-harrow-logo-cmyk-wtag-wr-jpg.jpg https://www.guineabissauhealthbulletin.com/article/908430187-altimmune-announces-closing-of-225-million-oversubscribed-public-offering-of-securities Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:00:00+00:00 Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities https://ml.globenewswire.com/media/362fbdfa-dc07-456c-9908-9e042540158a/small/altimmune-logo-png.png https://www.guineabissauhealthbulletin.com/article/908430189-cardiff-oncology-to-host-key-opinion-leader-discussion-on-onvansertib-s-promising-single-agent-activity Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:00:00+00:00 Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity https://ml.globenewswire.com/media/916adb81-8173-4fbe-8095-c284c4f44cd3/small/cardiff-jpg.jpg https://www.guineabissauhealthbulletin.com/article/908430195-sagimet-biosciences-provides-strategic-and-corporate-updates Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:00:00+00:00 Sagimet Biosciences Provides Strategic and Corporate Updates https://ml.globenewswire.com/media/e944daed-3f71-402b-bb23-82149e5c0d26/small/sagimet-logo-for-light-bg-fin-png.png https://www.guineabissauhealthbulletin.com/article/908430198-ocular-therapeutix-to-participate-in-may-scientific-and-investor-conferences Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:00:00+00:00 Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg https://www.guineabissauhealthbulletin.com/article/908430200-seer-board-of-directors-unanimously-rejects-revised-unsolicited-proposal-from-radoff-jec-group Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:00:00+00:00 Seer Board of Directors Unanimously Rejects Revised Unsolicited Proposal from Radoff-JEC Group https://ml.globenewswire.com/media/a5aaadad-13a1-4dbd-8ba2-d57cbbc610fb/small/seer-brandmark-rgb-full-jpg.jpg https://www.guineabissauhealthbulletin.com/article/908430206-ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-and-strengthening-ligand-s-position-as-a-leading-biopharma-royalty-aggregator Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:00:00+00:00 Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator https://ml.globenewswire.com/media/46cbb269-1ae4-4441-a46a-d782ffb436dc/small/xoma-royalty-2c-png.png https://www.guineabissauhealthbulletin.com/article/908430207-ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-and-strengthening-ligand-s-position-as-a-leading-biopharma-royalty-aggregator Guinea Bissau Health Bulletin en PressRelease 2026-04-27T11:00:00+00:00 Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator  https://ml.globenewswire.com/media/1fe91aa2-494e-4b30-89e8-cad771bbaabf/small/new-ligand-logo-png.png https://www.guineabissauhealthbulletin.com/article/908425638-fulcrum-therapeutics-appoints-josh-lehrer-to-its-board-of-directors Guinea Bissau Health Bulletin en PressRelease 2026-04-27T10:55:00+00:00 Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors https://ml.globenewswire.com/media/3434fc83-4bcf-4d3c-ae26-23e5b1fd4252/small/fulcrum-logo-primary-full-color-rgb-large-png.png https://www.guineabissauhealthbulletin.com/article/908425640-eton-pharmaceuticals-announces-initiation-of-clinical-study-for-product-candidate-et-700 Guinea Bissau Health Bulletin en PressRelease 2026-04-27T10:50:00+00:00 Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700 https://ml.globenewswire.com/media/db07cafa-b35c-4d61-a1a1-d330caf67ad2/small/eton-logo-png.png https://www.guineabissauhealthbulletin.com/article/908421856-conference-to-focus-on-how-artificial-intelligence-can-dramatically-reduce-workplace-injuries Guinea Bissau Health Bulletin en PressRelease 2026-04-27T10:30:00+00:00 Conference to focus on how artificial intelligence can dramatically reduce workplace injuries https://ml.globenewswire.com/media/NWJjMjI4MmQtZDhhYy00MTg2LWI0OTYtYmM4N2Y3ZWViNGI5LTUwMDE2MTY5NC0yMDI2LTA0LTI3LWVu/tiny/4S-Consulting-Inc-.png https://www.guineabissauhealthbulletin.com/article/908418144-relay-therapeutics-announces-clinical-data-for-zovegalisib-plus-atirmociclib-triplet-combination-supportive-of-further-development-in-frontline Guinea Bissau Health Bulletin en PressRelease 2026-04-27T10:00:00+00:00 Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer https://ml.globenewswire.com/media/079b6db5-ce81-4a81-9cde-d97f86c569ae/small/logo-banner-small-png.png https://www.guineabissauhealthbulletin.com/article/908418159-kfsh-highlights-scalable-ai-integration-model-at-c3-davos-of-healthcare-silicon-valley-summit Guinea Bissau Health Bulletin en PressRelease 2026-04-27T09:51:07+00:00 KFSH Highlights Scalable AI Integration Model at C3 Davos of Healthcare™ Silicon Valley Summit https://ml.globenewswire.com/media/9f73a943-28c0-4ee7-a796-2407051abbe7/small/logo-kfshrc-png.png https://www.guineabissauhealthbulletin.com/article/908401914-ataibeckley-and-psypan-receive-a-silver-award-in-2026-patient-participant-index-reflecting-ongoing-commitment-to-participant-informed-research Guinea Bissau Health Bulletin en PressRelease 2026-04-27T08:05:00+00:00 AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research https://ml.globenewswire.com/media/cea08bf4-0562-45ed-af5c-c9376c48a6eb/small/ataibeckley-horizontal-2color-png.png https://www.guineabissauhealthbulletin.com/article/908392273-fangzhou-publishes-2025-annual-report-advancing-ai-powered-chronic-care-strategy-for-2026 Guinea Bissau Health Bulletin en PressRelease 2026-04-27T06:52:35+00:00 Fangzhou Publishes 2025 Annual Report, Advancing AI-Powered Chronic Care Strategy for 2026 https://ml.globenewswire.com/media/294c081f-a526-49c8-925a-1e407972f343/small/logo-compressed-png.png https://www.guineabissauhealthbulletin.com/article/908381127-ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101-for-prevention-of-organ-rejection-in-heart-transplant Guinea Bissau Health Bulletin en PressRelease 2026-04-27T05:30:00+00:00 OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ose-logo-horizontal-rvb-png.png https://www.guineabissauhealthbulletin.com/article/908381134-ose-immunotherapeutics-se-f-licite-de-l-octroi-de-la-d-signation-de-m-dicament-orphelin-par-la-fda-du-pegrizeprument-vel-101-pour-la-pr-vention-du Guinea Bissau Health Bulletin en PressRelease 2026-04-27T05:30:00+00:00 OSE Immunotherapeutics se félicite de l'octroi de la désignation de médicament orphelin par la FDA du pegrizeprument (VEL-101) pour la prévention du rejet d’organe dans la transplantation cardiaque https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ https://www.guineabissauhealthbulletin.com/article/908378484-santhera-erh-lt-positive-stellungnahme-des-chmp-zur-ausweitung-der-anwendung-von-agamree-vamorolon-bei-p-diatrischen-dmd-patienten-ab-zwei-jahren Guinea Bissau Health Bulletin en PressRelease 2026-04-27T05:00:00+00:00 Santhera erhält positive Stellungnahme des CHMP zur Ausweitung der Anwendung von AGAMREE® (Vamorolon) bei pädiatrischen DMD-Patienten ab zwei Jahren in der EU https://ml-eu.globenewswire.com/media/63cd960e-70ce-4ba8-8984-92f72954c235/small/ https://www.guineabissauhealthbulletin.com/article/908378495-santhera-receives-positive-chmp-opinion-to-expand-agamree-vamorolone-use-in-pediatric-dmd-patients-aged-two-and-older-in-the-eu Guinea Bissau Health Bulletin en PressRelease 2026-04-27T05:00:00+00:00 Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU https://ml-eu.globenewswire.com/media/63cd960e-70ce-4ba8-8984-92f72954c235/small/logo-jpg.JPG https://www.guineabissauhealthbulletin.com/article/908367164-dark-horse-consulting-group-and-porton-advanced-announce-memorandum-of-understanding-providing-a-streamlined-path-to-conducting-iits-in-china Guinea Bissau Health Bulletin en PressRelease 2026-04-27T03:30:00+00:00 Dark Horse Consulting Group and Porton Advanced Announce Memorandum of Understanding Providing a Streamlined Path to Conducting IITs in China https://ml.globenewswire.com/media/b96e7c60-949b-4a7d-9d4e-8d9766cf8c87/small/2025-dhcg-logo-color-jpg.jpg https://www.guineabissauhealthbulletin.com/article/908282227-oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-a-trial-on-april-27-2026 Guinea Bissau Health Bulletin en PressRelease 2026-04-26T16:00:00+00:00 Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026 https://ml.globenewswire.com/media/3950d2d7-850d-459a-9e42-07c642a841c5/small/oruka-full-color-jpg.jpg https://www.guineabissauhealthbulletin.com/article/908279678-c3-davos-of-healthcare-silicon-valley-summit-opens-tomorrow-in-sunnyvale-with-kfsh Guinea Bissau Health Bulletin en PressRelease 2026-04-26T15:50:00+00:00 C3 Davos of Healthcare™ Silicon Valley Summit Opens Tomorrow in Sunnyvale with KFSH https://ml.globenewswire.com/media/9f73a943-28c0-4ee7-a796-2407051abbe7/small/logo-kfshrc-png.png https://www.guineabissauhealthbulletin.com/article/908279684-c3-davos-of-healthcare-silicon-valley-summit-tem-in-cio-amanh-em-sunnyvale-com-a-presen-a-do-kfsh Guinea Bissau Health Bulletin en PressRelease 2026-04-26T15:50:00+00:00 C3 Davos of Healthcare™ Silicon Valley Summit Tem Início Amanhã em Sunnyvale com a Presença do KFSH https://ml.globenewswire.com/media/9f73a943-28c0-4ee7-a796-2407051abbe7/small/logo-kfshrc-png.png https://www.guineabissauhealthbulletin.com/article/908279687-el-c3-davos-of-healthcare-silicon-valley-summit-se-inaugura-ma-ana-en-sunnyvale-con-kfsh Guinea Bissau Health Bulletin en PressRelease 2026-04-26T15:50:00+00:00 El C3 Davos of Healthcare™ Silicon Valley Summit se inaugura mañana en Sunnyvale con KFSH https://ml.globenewswire.com/media/9f73a943-28c0-4ee7-a796-2407051abbe7/small/logo-kfshrc-png.png https://www.guineabissauhealthbulletin.com/article/908179975-heroup-claims-evaluated-investigating-the-supplement-facts-about-hero-up-capsules-for-hardero-male-enhancement-support Guinea Bissau Health Bulletin en PressRelease 2026-04-26T01:13:17+00:00 HeroUp Claims Evaluated: Investigating the Supplement Facts About Hero Up Capsules for Hardero Male Enhancement Support https://zingfast.com/wp-content/uploads/2026/04/HeroUp-Male-Enhancement.jpg https://www.guineabissauhealthbulletin.com/article/908160348-quad-ed-under-investigation-safe-clinician-prescribed-ed-medication-using-sildenafil-tadalafil-vardenafil-and-apomorphine-for-men Guinea Bissau Health Bulletin en PressRelease 2026-04-25T22:24:56+00:00 Quad ED Under Investigation: Safe Clinician-Prescribed ED Medication Using Sildenafil, Tadalafil, Vardenafil and Apomorphine for Men https://zingfast.com/wp-content/uploads/2026/04/Quad-ED.jpg https://www.guineabissauhealthbulletin.com/article/908132022-healthrx-blood-support-claims-evaluated-the-health-rx-blood-pressure-optimizer-formula-under-investigation Guinea Bissau Health Bulletin en PressRelease 2026-04-25T19:10:06+00:00 HealthRX Blood Support Claims Evaluated: The Health RX Blood Pressure Optimizer Formula Under Investigation https://zingfast.com/wp-content/uploads/2026/04/Health-RX-Blood-Pressure-Optimizer-Formula.jpg https://www.guineabissauhealthbulletin.com/article/908097107-study-shows-implicity-s-new-agnostic-cloud-based-ai-algorithm-further-reduces-false-alerts-even-after-manufacturer-ai-filtering-in-modern-devices Guinea Bissau Health Bulletin en PressRelease 2026-04-25T15:00:00+00:00 Study Shows Implicity’s New Agnostic Cloud-Based AI Algorithm Further Reduces False Alerts Even After Manufacturer AI Filtering in Modern Devices https://ml.globenewswire.com/media/d7822800-7d4d-420d-aa7f-89a50a370756/small/implicity-logo-jpg.jpg https://www.guineabissauhealthbulletin.com/article/908094243-kfsh-advances-precision-surgery-through-in-house-3d-printing-program Guinea Bissau Health Bulletin en PressRelease 2026-04-25T14:45:00+00:00 KFSH Advances Precision Surgery Through In-House 3D Printing Program https://ml.globenewswire.com/media/9f73a943-28c0-4ee7-a796-2407051abbe7/small/logo-kfshrc-png.png https://www.guineabissauhealthbulletin.com/article/908094260-kfsh-avanza-en-la-cirug-a-de-precisi-n-mediante-un-programa-interno-de-impresi-n-3d Guinea Bissau Health Bulletin en PressRelease 2026-04-25T14:45:00+00:00 KFSH avanza en la cirugía de precisión mediante un programa interno de impresión 3D https://ml.globenewswire.com/media/9f73a943-28c0-4ee7-a796-2407051abbe7/small/logo-kfshrc-png.png https://www.guineabissauhealthbulletin.com/article/908094264-kfsh-avan-a-na-cirurgia-de-precis-o-com-o-programa-interno-de-impress-o-3d Guinea Bissau Health Bulletin en PressRelease 2026-04-25T14:45:00+00:00 KFSH Avança na Cirurgia de Precisão Com o Programa Interno de Impressão 3D https://ml.globenewswire.com/media/9f73a943-28c0-4ee7-a796-2407051abbe7/small/logo-kfshrc-png.png